Physician profile
Robert A Silverman
NPI 1881694651
$34,443.66
in general payments reported to CMS, 2019-2025
36 companies · $537 in 2025
The $537 reported for 2025 was more than what a typical Pediatric Dermatology provider received nationally (typical 2025 total: $302).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2020: $9,023 · 2021: $1,794 · 2022: $1,322 · 2023: $1,734 · 2024: $1,912 · 2025: $537.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,134 · Consulting Fee: $48.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,134.42 |
| Consulting Fee | $48.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $12,267.26 | 2019-2024 | Dupixent |
| Genzyme Corporation | $8,505.94 | 2019-2025 | |
| Pfizer INC. | $6,697.26 | 2019-2025 | |
| Abbvie INC. | $1,296.71 | 2019-2024 | Rinvoq, Skyrizi |
| Janssen Biotech, INC. | $1,061.40 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Incyte Corporation | $575.93 | 2021-2024 | Opzelura |
| Almirall LLC | $472.39 | 2019-2020 | |
| Lilly USA, LLC | $327.75 | 2019-2024 | Taltz, Olumiant, Ebglyss |
| Leo Pharma INC. | $324.99 | 2019-2024 | Adbry |
| Galderma Laboratories, L.P. | $275.53 | 2019-2024 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $230.50 | 2019-2024 | Cabtreo, Arazlo, Jublia |
| Novartis Pharmaceuticals Corporation | $228.91 | 2023-2024 | |
| Arcutis Biotherapeutics, INC. | $214.72 | 2023-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $211.74 | 2019-2023 | Winlevi, Absorica Ld |
| Krystal Biotech INC | $197.21 | 2023 | Vyjuvek |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $146.88 | 2023-2024 | Vtama |
| Verrica Pharmaceuticals INC. | $140.52 | 2023-2024 | Ycanth |
| Celgene Corporation | $124.36 | 2019 | |
| Ucb, INC. | $123.74 | 2019 | |
| Janssen Research & Development, LLC | $122.98 | 2024 | |
| Dermira, INC. | $113.35 | 2019 | |
| Allergan, INC. | $113.12 | 2020 | |
| Janssen Scientific Affairs, LLC | $103.92 | 2019 | |
| Encore Dermatology INC. | $91.61 | 2019-2020 | |
| Epi Health, LLC | $72.32 | 2019-2020 | |
| Vyne Pharmaceuticals INC. | $65.95 | 2020 | |
| Mayne Pharma Commercial LLC | $50.17 | 2019-2020 | |
| Adma Biomanufacturing LLC | $48.34 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.77 | 2024-2025 | Spevigo |
| Regeneron Pharmaceuticals, INC. | $39.18 | 2022-2024 | Dupixent |
| Journey Medical Corporation | $36.03 | 2019-2022 | |
| Strata Skin Sciences, INC. | $33.29 | 2019-2024 | Xtrac |
| Convatec INC. | $25.76 | 2024 | |
| Nobelpharma America, LLC | $23.63 | 2023 | |
| Amgen INC. | $22.29 | 2024 | Otezla |
| Biofrontera INC. | $14.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Silverman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.